Log In Or Register For Full Access
Close
Username
Password
 Forgot username or password?
Not Registered?
Leaving This Site
Close
You are now leaving GSKSource.
Please note that links to non-GSK sites are provided as a courtesy to GSKSource users, but that GSK is not responsible for the content found therein.
                                    
GSK Employee Access
Close
GlaxoSmithKline employees must use their GSK laptop/desktop and must be logged into the GSK network to access this site.
If you are logged into the GSK network, please select continue to access the site.
                                    
Important Notice
This site is intended for US Healthcare Professionals. By clicking continue, you are acknowledging that you are a US Healthcare Professional.
Boostrix
BOOSTRIX®
(Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)
Product Overview

While Adacel® is indicated for patients from
10-64 years of age1

BOOSTRIX® is indicated for the widest age range
of patients (from 10 years of age and older)1,2

BOOSTRIX® is the ONLY Tdap* vaccines approved
by the FDA† for adults 65 years of age and older1,2
Learn more

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.

Important Safety Information

  • Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
  • The tip caps of the prefilled syringes for BOOSTRIX may contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals
  • The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
  • Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
  • In clinical studies, common adverse reactions were pain, redness, and swelling at the injection site, increase in arm circumference of injected arm, headache, fatigue, gastrointestinal symptoms, and fever
  • Vaccination with BOOSTRIX may not result in protection in all vaccine recipients

  • BOOSTRIX® is indicated for the widest age range of patients (from 10 years of age and older)1,2
  • BOOSTRIX is the ONLY Tdap* vaccine approved by the FDA† for adults 65 years of age and older1,2 Learn More
* Tetanus, diphtheria, and acellular pertussis.
† US Food and Drug Administration.

Adacel is a registered trademark of sanofi pasteur group, and its subsidiaries.

BOOSTRIX is a registered trademark of the GlaxoSmithKline group of companies.


Required Information

A state licence number is required to be on file for the state in which samples will be delivered
State Licence Number Licensing State